Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- PMDA Looks to New Pre-Application Meetings to Shed Review Time
November 14, 2014
- New Japan NIH Head Asks Pharma Industry to Suggest Ideas for Benefit of Japanese People
November 13, 2014
- PMDA to Expand Consultation Services for Clinical Trials Initiated by Academia
November 12, 2014
- Blue, Yellow Letters to Cover Regenerative Medicines
November 11, 2014
- MHLW Mulls Creating Rules under Law for Patient-Initiated Mixed-Care System
November 11, 2014
- PAFSC First Committee to Discuss Takeda’s Vonoprazan on Nov. 21
November 11, 2014
- US FDA Withdraws Tentative Approvals for 2 Generic Drugs of Ranbaxy
November 11, 2014
- 5 Experts Likely to Review Regenerative Medicines for Expedited Senshin-Iryo Scheme
November 10, 2014
- Health Ministry Panel Includes Legal Regulations for Clinical Research in Draft Outline
November 10, 2014
- Chuikyo OKs Patient-Initiated Mixed-Care System, Use of Investigational Drugs for Non-Enrollable Patients
November 7, 2014
- Chuikyo Approves Insurance Coverage for Regenerative Medicine Products upon Conditional Approval
November 7, 2014
- PMDA Assessing Reminyl for Risk of Acute Generalized Exanthematous Pustulosis
November 6, 2014
- MHLW Issues Notifications on Drug/Medical Device Combination Products
November 6, 2014
- Sept. Drug Price Settlement Rate at 92.6% as Big Hospitals, Pharmacies Take Quantum Leap
November 6, 2014
- Editor’s Pick: Five Healthcare News Headlines for October 20 - October 31
November 5, 2014
- PMDA Establishes Office of Generic Drugs to Expedite Review and Consultation for Generic Drugs
November 4, 2014
- Cabinet OKs Appointment of Keio Prof as Japan NIH Head
October 31, 2014
- MHLW to Issue Notification with Survey Form on Adverse Reactions to HPV Vaccines
October 31, 2014
- Lantus Biosimilars Likely to Be OKed by Year-End: First Committee
October 30, 2014
- Welfare Recipients Should Pay Difference between Generic and Branded Drug Prices: MOF
October 29, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…